Table 1 Summary of randomized clinical studies of moxibustion for ulcerative colitis with parallel design
From: Moxibustion for ulcerative colitis: a systematic review and meta-analysis
First author (Year) [ref] | Sample size (M/F) Duration of disease Age (range) Setting* (author's affiliation) | Experimental intervention | Control intervention | Response rate§ (basis of assessment) |
|---|---|---|---|---|
Wen (2003) [16] | 69 (35/34) (A) 6 mon-14 yrs (B) 4 mon-16 yrs 23-69 yrs n.r. (TCM hospital) | (A) Moxa [once daily for 12 days (1 session), 3 day intervals between courses, total 6 sessions n = 39] Indirect | (B) Sulfasalazine (SASP, oral, 1 g × 4/d, for 3 months, n = 30) | A(89.8%, 35/39); B(66.8%, 20/30) P < 0.05 (Physician's assessment) |
Wu (1999) [17] | 151 (n.r.) (A) 6 mon-18 yrs (B) 4 mon-16 yrs (C) 4 mon-17 yrs 25-70 yrs n.r. (TCM institute and Western hospital) | (A) Moxa I [once daily for 12 days (1 session), 3 day intervals between courses, total 6 sessions n = 65] (B) Moxa II(same as A, n = 56) Indirect | (C) Sulfasalazine (SASP only, oral, early: 1 g × 4/d, firmly: 0.5 g × 4/d, for 3 months, n = 30) | A(92.3%, 60/65); B(89.3%, 50/56); C (66.7%, 20/30) A, C: P < 0.01; B, C: P < 0.05 (Physician's assessment) |
Ding (2009) [18] | 61 (32/29) (A) 3 mon-20 yrs (B) 3 mon-17 yrs 19-71 yrs n.r. (Western hospital) | (A) Moxa [20 min, once daily for 2 months, n = 30] Indirect (ginger) | (B) Sulphasalazine (oral, 1 g × 4/d, for 1 month, n = 31) | A(100%, 30/30); B(90.3%, 28/31) P < 0.05 (Physician's assessment, endoscopy) |
Wang (2006) [19] | 60 (28/32) (A) 0.5-12 yrs (B) 0.6-13 yrs 27-54 yrs TCM hospital and private clinics (TCM hospital and private clinics) | (A) Moxa [once daily for 12 days (1 session), 3 day intervals between courses, total 3 sessions n = 30] Indirect | (B) Sulphasalazine (1.0 g × 4/d) and Metronidazole (0.2 g × 3/d), oral, [once daily for 10 days (1 session), 3 day intervals between courses, total 3 sessions n = 30] | A(86.7%, 26/30); B(66.7%, 20/30) P < 0.05 (Physician's assessment, endoscopy) |
Zhou (2003) [20] | 66 (31/35) 2-8 yrs 19-50 yrs n.r. (TCM hospital) | (A) Moxa [once daily for 10 days (1 session), 3 day intervals between courses, total 3 sessions n = 34] Indirect (ginger) | (B) Sulfasalazine (SASP, oral, 0.5 g × 4/d), for 30 days, n = 32] plus Prednisone [(oral, 10 mg × 4/d but reduce to 10 mg/d if getting a more stable state) | A(97.1%, 33/34); B(71.9%, 23/32) P < 0.05 (Physician's assessment, endoscopy) |